Verdun, France
Verdun, France

Time filter

Source Type

Samama M.M.,Laboratoire Biomnis | Samama M.M.,Groupe hospitalier Broca Cochin Hotel Dieu | Guinet C.,Laboratoire Biomnis | Le Flem L.,Laboratoire Biomnis
Bio Tribune Magazine | Year: 2011

Two new orally active anticoagulants - Dabigatran etexilate prodrug or Pradaxa® inhibitor of factor IIa and Rivaroxaban or Xarelto® inhibitor of factor Xa - have received the European and Canadian authorizations to be launched on the market for preventing venous thromboembolic accidents in major orthopedic surgery. Dabigatran is registered in North America for patients with atrial fibrillation. One of their advantages is that they do not require regular monitoring of coagulation. Nevertheless, in a small number of particular clinical settings, it might become necessary to measure their anticoagulant activity. This implies the choice of appropriate techniques and an interpretation of the results according to the time between the blood collection and the taking of the drug. Studies have used pools of normal plasmas enriched with increasing concentrations of Rivaroxaban or Dabigatran, or plasmas of treated patients. One must make a distinction between the simple tests, which are very easy to make, like prothrombin time preferred for Rivaroxaban rather than for Dabigatran, but not specific, and the tests like anti-Xa activity measurement less easily available, but specific. The activated partial thromboplastin time, and preferably the modified thrombin time (Hemoclot), and the anti-IIa activity measurement will be used for Dabigatran. In all these techniques, the use of calibrated plasmas containing known quantities of drug allow to express the results in ng or in μg/mL of plasma, in order to compare them to the values obtained in patients. © 2011 Springer Verlag France.


PubMed | Marseille University Hospital Center, Guys Hospital, Medical Genetics Unit, Laboratoire Biomnis and 11 more.
Type: Journal Article | Journal: European journal of human genetics : EJHG | Year: 2015

6q16 deletions have been described in patients with a Prader-Willi-like (PWS-like) phenotype. Recent studies have shown that certain rare single-minded 1 (SIM1) loss-of-function variants were associated with a high intra-familial risk for obesity with or without features of PWS-like syndrome. Although SIM1 seems to have a key role in the phenotype of patients carrying 6q16 deletions, some data support a contribution of other genes, such as GRIK2, to explain associated behavioural problems. We describe 15 new patients in whom de novo 6q16 deletions were characterised by comparative genomic hybridisation or single-nucleotide polymorphism (SNP) array analysis, including the first patient with fetopathological data. This fetus showed dysmorphic facial features, cerebellar and cerebral migration defects with neuronal heterotopias, and fusion of brain nuclei. The size of the deletion in the 14 living patients ranged from 1.73 to 7.84Mb, and the fetus had the largest deletion (14Mb). Genotype-phenotype correlations confirmed the major role for SIM1 haploinsufficiency in obesity and the PWS-like phenotype. Nevertheless, only 8 of 13 patients with SIM1 deletion exhibited obesity, in agreement with incomplete penetrance of SIM1 haploinsufficiency. This study in the largest series reported to date confirms that the PWS-like phenotype is strongly linked to 6q16.2q16.3 deletions and varies considerably in its clinical expression. The possible involvement of other genes in the 6q16.2q16.3-deletion phenotype is discussed.


PubMed | Service de gynecologie, Service de gastro enterologie, Service de pediatrie generale, Nancy University Hospital Center and 37 more.
Type: Journal Article | Journal: Geriatrie et psychologie neuropsychiatrie du vieillissement | Year: 2016

The number of serum 25-hydroxyvitamin D (25OHD) assays has increased tenfold in France in less than 10 years, sometimes for invalidated reasons. In 2013, the French National Authority for Health (Haute autorit de sant, or HAS) limited the indications for serum 25OHD measurements to rickets/osteomalacia, older adults with recurrent falls, monitoring of kidney transplant in adults, and surgical treatment of obesity in adults. Our aim here was to note that other indications for serum 25OHD measurements are supported by previous literature and by a number of national and international recommendations, in particular the following: any situation of bone fragility, any chronic renal failure <45 mL/min/1.73m


Samama M.M.,Groupe hospitalier Broca Cochin | Samama M.M.,Laboratoire Biomnis | Gerotziafas G.,Hopital Tenon
Bio Tribune Magazine | Year: 2011

Vitamin K antagonists (VKA) and heparins are the commonly used therapeutics in the prevention of venous and arterial thromboembolic episodes. They have numerous advantages and few flaws: iatrogenicity and compulsory biological monitoring for the VKA, and activity limited to the parenteral way for heparins. Three new oral anticoagulants, direct inhibitors of factor Xa (Rivaroxaban, Apixaban) or of factor IIa or thrombin (Dabigatran Etexilate), do not need coagulation monitoring. The diet does not influence the activity of these 3 new molecules. A small number of drugs can modify their anticoagulant activity. The thromboprophylaxis in major orthopedic surgery and the non valvular atrial fibrillation are registered by the Health Authorities. Their use in the treatment of venous thromboembolic episodes and the prevention of recurrence or secondary prevention has not been yet validated by the Health Authorities. The physician's information and the patient's education are strongly recommended for the success of this therapeutic revolution. © 2011 Springer Verlag France.


Servant-Delmas A.,Sanguine | Mercier-Darty M.,Sanguine | Ly T.D.,Laboratoire Biomnis | Wind F.,Etablissement Francais du Sang | And 3 more authors.
Journal of Clinical Virology | Year: 2012

Background: Natural variation and mutations in the envelope protein (S) of hepatitis B virus can translate into HBsAg variants no longer detectable by conventional HBsAg assays. Objectives: The aim of the study was to assess the performance of 13 commercial assays currently used for screening and clinical analysis of HBsAg variants. Study design: The limit of detection (LOD) for each assay was established using two reference standards (WHO HBsAg 00/588 and the SFTS French reference). Sensitivity was evaluated using different panels. Panel 1 included 25 recombinant HBs variants at three concentrations, panels 2 and 4 included 8 recombinant HBsAg variants and 9 wild-type proteins (genotypes A-F), respectively, panel 3 included 16 natural HBsAg variants. Results: LODs ranged from 0.011 to 0.095. IU/ml with the WHO standard, and from 0.021 to 0.326. ng/ml with the French reference. The overall percentage of positive signals using HBsAg variants ranged from 62.9% to 97.9%. Three substitutions: T123, D144A and G145, were negative at all concentrations with at least one assay. Discussion: Our findings show that, although they fulfil CE requirements for analytical sensitivity (LODs below 0.13. IU/ml), HBsAg assays may vary in their capacity to detect HBsAg variants. This limit in diagnosis performance should encourage the health regulatory agencies to include HBsAg variant panels in the evaluation process. © 2012 Elsevier B.V.


PubMed | Center National Of Reference Des Mycobacteries Et Of La Resistance Aux Antituberculeux, Laboratoire Biomnis, Montpellier University and CHRU Montpellier
Type: | Journal: Annals of clinical microbiology and antimicrobials | Year: 2016

The agar dilution method is currently considered as the reference method for Mycobacterium marinum drug susceptibility testing (DST). As it is time-consuming, alternative methods, such as the E-test, were evaluated for M. marinum DST, but without success. The SLOMYCO Sensititre() panel, recently commercialized by TREK Diagnostic Systems (Cleveland, OH), can be used for DST in slow-growing mycobacteria and for antimicrobial agents recommended by the Clinical and Laboratory Standards Institute (CLSI) for M. marinum DST. The main goal of this work was to evaluate the SLOMYCO Sensititre() panel method for DST in M. marinum isolates from human patients and fish relative to the reference agar dilution method.The reproducibility of the minimum inhibitory concentration (MIC) determination (1 log2 dilution) was very good for both the agar dilution method and SLOMYCO Sensititre() panel (>90% agreement). The percentage essential agreement between methods varied, depending on the drug: between 97 and 75% for ciprofloxacin, moxifloxacin, linezolid, isoniazid, clarithromycin, amikacin, rifabutin and rifampin, 74% for trimethoprim, 72% for doxycycline, 70% for sulfamethoxazole, 59% for streptomycin, 33% for ethambutol and only 2.2% for ethionamide. When the agar dilution and SLOMYCO Sensititre() panel results were converted into interpretive criteria, the category agreement was 100% for amikacin, ciprofloxacin, clarithromycin, moxifloxacin, rifabutin, sulfamethoxazole and trimethoprim, 98% for ethambutol and 96% for rifampin and no agreement for doxycycline.The SLOMYCO Sensititre() panel method could provide a potential alternative to the reference agar dilution method, when DST in M. marinum is required, except for doxycycline.


Gonzalo P.,University of Lyon | Pecquet M.,University of Lyon | Bon C.,University of Lyon | Gonzalo S.,Laboratoire Biomnis | And 3 more authors.
Clinica Chimica Acta | Year: 2012

Background: The CDT assay used to detect chronic alcohol abuse is difficult with cirrhotic patients. This article describes the performances of several CDT assays in case of cirrhosis. The CDT-Capillarys assay by capillary zone electrophoresis was used for initial testing. Two additional methods were tested as putative confirmatory methods. Methods: 110 patients with known hepatic status had their CDT measured by the Capillarys2 or alternative methods. Self-reported alcohol intake was used to assess the performances of CDT assays. Results: Capillarys2 performance was lower in case of cirrhosis, many electropherograms displaying various abnormalities. We used the proper separation of the di- and tri-sialotransferrin peaks to select reliable profiles. This selection led to the classification of cirrhotic and non-cirrhotic patients in abusers and abstainers with similar performances. However, no interpretation was available for 54% of the cirrhotic patients and neither the BioRad %CDT by HPLC test, nor the Siemens N-Latex CDT kit was suitable as confirmatory methods for these samples. Conclusions: An attentive profile examination is required for the validation of Capillarys CDT results of cirrhotic patients. Reliability is significantly improved when samples with an improper separation are excluded. To date, no commercial test can confirm the excluded samples. © 2012 Elsevier B.V.

Loading Laboratoire Biomnis collaborators
Loading Laboratoire Biomnis collaborators